Compare VanEck Australian Floating Rate ETF (FLOT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Australian Floating Rate ETF vs State Street SPDR S&P Biotech ETF — how do they compare? VanEck Australian Floating Rate ETF trades at $50.96 (market cap $11.24B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: VanEck Australian Floating Rate ETF and State Street SPDR S&P Biotech ETF are close in size by market cap, and State Street SPDR S&P Biotech ETF is more actively traded (12,903,266 versus 1,872,962). Which is the better fit depends on your goals — on Pluang, investors hold VanEck Australian Floating Rate ETF for 21 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| FLOT | XBI | |
|---|---|---|
Market Cap | $11.24B | $10.11B |
Volume | 1,872,962 | 12,903,266 |
Sector | Fixed Income | Broad Market / Factor |
52-Week High | $51.07 | $169.55 |
52-Week Low | $50.72 | $104.99 |
Typical Hold Time | 21 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLOT trades at $50.96 with minimal daily movement (+0.1%) amid bearish technical signals. The ETF faces concentration risk with 47% bank exposure while benefiting from floating rate exposure during Fed tightening cycles. Recent dividend payments of $0.17-0.18 reflect current yield environment, though technical indicators show strong selling pressure with moving averages and ADX signaling bearish momentum.
The floating rate structure positions FLOT to benefit from continued Fed hawkishness, but high bank concentration presents sector-specific risks. Current technical weakness suggests near-term pressure, while the fund's yield advantage over cash equivalents remains attractive for income-focused investors in rising rate environments.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About VanEck Australian Floating Rate ETF
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
